Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia - Wikidata - wikimedia - TriplyDB

Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia

Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia

http://www.wikidata.org/entity/Q36422666

about

Microcolony imaging of Aspergillus fumigatus treated with echinocandins reveals both fungistatic and fungicidal activities Micafungin use in children.Role of trehalose biosynthesis in Aspergillus fumigatus development, stress response, and virulence Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections Pharmacokinetics and safety of intravitreal caspofungin.Polyphasic identification and susceptibility to seven antifungals of 102 Aspergillus isolates recovered from immunocompromised hosts in Greece.Micafungin in the treatment of invasive candidiasis and invasive aspergillosis In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network.Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.Antimicrobial dosing in acute renal replacement.Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions Paradoxical echinocandin activity: a limited in vitro phenomenon?Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.A clinical review of echinocandins in pediatric patients.Echinocandin pharmacodynamics: review and clinical implications.Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?Caspofungin therapy in immunocompromised children and neonates.The Eagle-like effect of echinocandins: what's in a name?Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Echinocandins: The Expanding Antifungal Armamentarium.Caspofungin Increases Fungal Chitin and Eosinophil and γδ T Cell-Dependent Pathology in Invasive Aspergillosis.Potential Microbiological Effects of Higher Dosing of Echinocandins.Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin Comparative Evaluation of Sensititre YeastOne and CLSI M38-A2 Reference Method for Antifungal Susceptibility Testing of Aspergillus spp. against Echinocandins.Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.Caspofungin Treatment of Aspergillus fumigatus Results in ChsG-Dependent Upregulation of Chitin Synthesis and the Formation of Chitin-Rich Microcolonies.Fungal echinocandin resistance.The composition of the culture medium influences the β-1,3-glucan metabolism of Aspergillus fumigatus and the antifungal activity of inhibitors of β-1,3-glucan synthesis.Bronchopulmonary disposition of micafungin in healthy adult volunteers.Profiling the Aspergillus fumigatus proteome in response to caspofungin.Anidulafungin in combination with amphotericin B against Aspergillus fumigatus.In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.Filter Adsorption of Anidulafungin to a Polysulfone-Based Hemofilter During CVVHD In Vitro.Recent Insights into the Paradoxical Effect of Echinocandins.A new marker of echinocandins activity in an in vitro PK/PD model correlates with an animal model of Aspergillus fumigatus infection.

P2860

Q28383749-B61E65CD-A476-4906-B84A-C90A9C38D649 Q33397111-BCB71393-2AB7-4E0A-B22A-32D3537C0047 Q33963040-1B2149FE-6815-4C4E-A13F-BB6DF134B7E7 Q34108585-E964D605-19D7-4814-9196-DCCC5383C1FC Q34597632-2999B2B8-9793-4901-862A-46CB6C3E2643 Q35005122-8B046989-F64F-4886-998F-5BC9B44480EA Q35026516-CF645686-D110-4084-B6EF-0068F49D1371 Q35139558-B557C069-FE3A-496E-9A46-6C19EEBEB064 Q36757617-E76434B2-34E9-4F3D-AEAB-46BD4051111A Q37190686-49431E3C-6326-447B-B58D-BFA42F7DFD1A Q37252494-09C1AA4B-7F26-426A-B51C-61B8DCB7C08E Q37263780-79E5D820-3C11-4750-BFC6-A79842AD1681 Q37405284-0D7D1E0D-F93B-40DF-8AA2-837ED050A413 Q37450705-52EC5B7C-CB87-4652-8DB3-C2EE39DAFA34 Q37608276-45AC4DE5-ACD1-4DDB-814B-3D169C0FCC86 Q37653647-5ADAAD31-26B1-4C16-812F-1F92FB812CC0 Q37718385-814D86A7-51B1-4545-9AB2-3C37FED3F978 Q37785979-1ED94DB0-A349-4F8B-824A-30A9CB3A8DF1 Q37854724-759FB50F-BF82-4785-BFF2-A6A5FEB09806 Q37854725-4437245E-BD70-48B0-93BF-D832DDE3B02D Q38153458-1D40B33D-7007-4C4B-8661-98C12B7EE7C6 Q38586680-1E11DDE3-1E5C-4C97-B72A-FEAF7AB0D3E2 Q38633102-C606822C-3AE6-4E14-BD3D-101445370E19 Q38676508-C1B2BB51-EC2A-4720-BCD3-AE08E8F47BA5 Q38942828-5217023A-CD01-47DD-A3D5-70075DC62162 Q39895162-00785A0A-7BB9-4E0F-8E91-6DEA563F0FE5 Q40283086-D4F1723D-33D4-4649-8F29-3D727B0BF5AF Q40587101-79350DF3-93A0-436F-B9C0-DF64F6970001 Q40743249-EA39F482-4930-4460-8408-E1685F03D780 Q41848811-6C34335D-C969-48D0-BFB0-64CD346A0D87 Q42047835-CBE4BA37-FCCC-400D-AC48-079ABC05EA31 Q42157206-2253D1F8-CDCC-418C-BDE7-57FB746B3496 Q42163853-F7978474-A2E9-4778-A681-F3339F0A6E4B Q42545764-A1F3DCA6-281D-4095-A1A0-FD40DA220BB8 Q42576501-C86FDB11-966F-4B10-A019-EBF551CD6A8C Q43287630-1A097AA5-D51E-4EFE-9867-1617456E45CA Q47205373-5C1B18AD-DA78-4CE8-BC9E-D3BB236A4F8C Q48192025-A2D79EB7-2B16-41D2-B34C-DBD204D3A5D6 Q49679966-A69CE20C-4E0B-4C36-9B94-252763826B25 Q49792124-AAC4568A-68C1-4910-8AD9-926CEE907BB4

P2860

Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia

http://www.wikidata.org/entity/Q36422666

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Comparative in vitro pharmacod ...... germinated Aspergillus conidia

@ast

Comparative in vitro pharmacod ...... germinated Aspergillus conidia

@en

type

label

Comparative in vitro pharmacod ...... germinated Aspergillus conidia

@ast

Comparative in vitro pharmacod ...... germinated Aspergillus conidia

@en

prefLabel

Comparative in vitro pharmacod ...... germinated Aspergillus conidia

@ast

Comparative in vitro pharmacod ...... germinated Aspergillus conidia

@en

P1433

Q36422666-266E9652-7C04-4469-9BC1-BFD85D3D3171

P1476

Q36422666-33F48B10-1AF8-449B-B618-89BDBE1F952C

P2093

Q36422666-114EA222-A2DD-4DA6-9FEC-CAF08D6AE097

Q36422666-25BC50FC-7F61-442C-B2DD-55C736767DF9

Q36422666-369F3B98-EBFE-4E3E-A3DC-6F543E82B57D

Q36422666-6742B6D8-9335-499E-953D-CBC828309293

P2860

Q36422666-012B88E8-3A0E-4ED4-AB5F-1ADE131232F9

Q36422666-131DBD38-B8F5-48EB-A9FB-3D2DAD022D47

Q36422666-183E9587-3F2E-4A2F-8922-3AF5728368B0

Q36422666-1E3F673D-8EB5-4BE3-BA64-F9F136B1EC16

Q36422666-2BA8EB0F-0CB1-4829-B3E2-5B2FAB9254D1

Q36422666-3C0EE768-17EA-4D6A-9F4E-C74513D90554

Q36422666-4772AFC0-7317-49F0-AABF-EE5007CC2405

Q36422666-510DC31D-BFDE-4CC6-AA0E-B60173B2EF20

Q36422666-54A40518-4183-447A-9487-871E1D3F2DF2

Q36422666-56FD1542-542D-4703-80C0-B5CE7917EE7B

P304

Q36422666-A1968F6D-872C-445A-8486-2EBB62F8C4ED

P31

Q36422666-44D07F84-7AE7-4A54-A548-588BC6B9843B

P356

Q36422666-48BF8CB8-8664-42B9-8E61-D1FBC0C8F808

P407

Q36422666-4DCBADE9-C2D0-472B-BC9C-8A03FD8AD0C9

P433

Q36422666-0C0B1529-0F7B-41F7-8EED-FD7D0876A5DD

P478

Q36422666-16FE75C1-5A91-4AFB-8BD7-42C461B7EEF0

P50

Q36422666-FB055E2B-0EFF-47B6-BB5B-AEFC0395B5FA

P577

Q36422666-A980EBB6-EB34-436B-870A-6CC61FE678C8

P698

Q36422666-8C400E87-B4B6-43EF-84F5-FCE867DF71D0

P932

Q36422666-3C7E1765-146C-4436-BAFD-3520C036B4C7

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Comparative in vitro pharmacod ...... germinated Aspergillus conidia

@en

P2093

Charalampos Antachopoulos

http://www.w3.org/2001/XMLSchema#string

Joseph Meletiadis

http://www.w3.org/2001/XMLSchema#string

Thomas J Walsh

http://www.w3.org/2001/XMLSchema#string

Tin Sein

http://www.w3.org/2001/XMLSchema#string

P2860

Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

Echinocandin antifungal drugs

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.

Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for ant

Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.

Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).

1,3-beta-Glucan synthase: a useful target for antifungal drugs.

The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.

P304

321-328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00699-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Emmanuel Roilides

P577

2007-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17938191

http://www.w3.org/2001/XMLSchema#string

P932

2223904

http://www.w3.org/2001/XMLSchema#string